Best student loans for nursing school

Federal loan changes effective July 1, 2026, cap Direct Unsubsidized borrowing for most eligible professional students at $50,000 per year and $200,000 aggregate, while generally ending access to Grad PLUS loans for new graduate and professional students. The article compares private nursing-school loan options, noting SoFi fixed APRs of 2.99%–15.99% and variable APRs of 4.64%–15.99%, plus lender-specific features such as income-based payments, grace periods and co-signer release. Private loans can fill funding gaps but generally lack federal protections, and rates and eligibility vary by borrower and program.

Analysis

The investable mechanism is a possible shift of incremental graduate-school funding from federal programs to private lenders—not a demonstrated step-up in lender earnings. The beneficiary case for SoFi Technologies (SOFI) and SLM Corporation (SLM) is conditional: the article provides no nursing-loan origination, approval, or balance data, and its affiliate-sponsored lender rankings are not evidence of market share. A narrow nursing segment is unlikely to matter to either company absent broader adoption across graduate programs.

The second-order risk is adverse selection. Borrowers unable to access federal funding may be more credit-constrained, while private loans lack equivalent federal protections; higher application volume could therefore bring weaker risk-adjusted returns rather than better growth. Conversely, schools could respond with aid, tuition restraint, or enrollment changes, limiting private-loan demand. Employer and hospital tuition support may also absorb some funding gap.

Near term, treat this as a watch item, not an earnings catalyst. Over 1–3 months, verify lender disclosures for graduate/health-profession originations, approval rates, pricing, and delinquencies. Over 6–18 months, monitor whether the funding change persists and expands beyond nursing; policy reversal or exceptions could unwind the substitution thesis. The contrarian point is that headline private-loan opportunity may overstate lender economics: the binding constraint may be borrower repayment capacity, not availability of credit. No valuation or portfolio-impact conclusion is supportable from the article alone.

Key Decisions for Investors

• No standalone trade on this article. Do not infer a material SOFI or SLM revenue tailwind from a product roundup or from federal borrowing limits alone.
• Set an alert for SOFI and SLM disclosures on private graduate/health-profession loan originations, pricing, approval mix, and delinquency/charge-off trends. Consider a relative-value position only if incremental originations appear material and credit performance remains stable; otherwise the growth signal is not risk-adjusted.
• Falsify the private-lender upside thesis if subsequent disclosures show little graduate-loan growth, worsening credit performance, or evidence that school aid, employer support, enrollment shifts, or policy changes are absorbing the funding gap.